SCHEMBL1101034

SCHEMBL1101034

C[C@H]1CO[C@@H](CO)S1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4454738 0.78
SCHEMBL10546750 0.73
SCHEMBL9709235 0.67
SCHEMBL7927975 0.62
SCHEMBL3872988 0.62
Propylene Oxide SCHEMBL7556563 0.58 CHRM2 (0.37)
Propylene Oxide SCHEMBL168597 0.58
Propylene Oxide SCHEMBL193535 0.58
SCHEMBL1122327 0.58
Propylene Oxide SCHEMBL9874479 0.58 CHRM2 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354546-B2 Process for manufacture of optically active 2-(acyloxymethyl)-1,3-oxathiolanes Vertichem Corporation (CA) 2013-01-15 US disclosed
US-20120157693-A1 Process for Manufacture of Optically Active 2-(Acyloxymethyl)-1,3-Oxathiolanes THESIS CHEMISTRY, LLC (US) 2012-06-21 US disclosed
US-8153416-B2 Process for manufacture of optically active 2-(acyloxymethyl)-1,3-oxathiolanes using enzymatic resolution THESIS CHEMISTRY, LLC (US) 2012-04-10 US disclosed
US-7807653-B2 Nucleotide mimics and their prodrugs BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2010-10-05 US disclosed
US-7807653-B2 Nucleotide mimics and their prodrugs BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2010-10-05 US disclosed
US-20100143978-A1 Process for Manufacture of Optically Active 2-(Acyloxymethyl)-1,3-Oxathiolanes THESIS CHEMISTRY, LLC (US) 2010-06-10 US disclosed
US-7598230-B2 For the treatment of viral infections, microbial infections, and proliferative disorders; contain di- or triphosphate moeity mimetics, such as those containing boron anions BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2009-10-06 US disclosed
US-7598230-B2 For the treatment of viral infections, microbial infections, and proliferative disorders; contain di- or triphosphate moeity mimetics, such as those containing boron anions BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2009-10-06 US disclosed
US-20070265224-A1 Nucleotide mimics and their prodrugs BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2007-11-15 US disclosed
US-20070265224-A1 Nucleotide mimics and their prodrugs BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2007-11-15 US disclosed
US-20070259832-A1 Nucleotide mimics and their prodrugs BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2007-11-08 US disclosed
US-20070259832-A1 Nucleotide mimics and their prodrugs BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2007-11-08 US disclosed
US-7285658-B2 Nucleotide mimics and their prodrugs BIOTA, INC. (US) 2007-10-23 US disclosed
US-7285658-B2 Nucleotide mimics and their prodrugs BIOTA, INC. (US) 2007-10-23 US disclosed